Truncation of the GABAA-Receptor γ2 Subunit in a Family with Generalized Epilepsy with Febrile Seizures Plus  by Harkin, Louise A. et al.
Am. J. Hum. Genet. 70:530–536, 2002
530
Report
Truncation of the GABAA-Receptor g2 Subunit in a Family
with Generalized Epilepsy with Febrile Seizures Plus
Louise A. Harkin,1,2 David N. Bowser,4 Leanne M. Dibbens,1,2 Rita Singh,5,6 Fiona Phillips,5,6
Robyn H. Wallace,1,2 Michaella C. Richards,1 David A. Williams,4 John C. Mulley,1,3
Samuel F. Berkovic,5,6 Ingrid E. Scheffer,5,6,7,8 and Steven Petrou4
1Centre for Medical Genetics, Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital, Adelaide, and
Departments of 2Paediatrics and 3Genetics, University of Adelaide, Adelaide, South Australia, Australia; 4Department of Physiology and
5Epilepsy Research Institute and Department of Medicine (Neurology), University of Melbourne, 6Austin and Repatriation Medical Centre,
7Department of Neurology, Royal Children’s Hospital, and 8Department of Neurosciences, Monash Medical Centre, Melbourne, Victoria,
Australia
Recent findings from studies of two families have shown that mutations in the GABAA-receptor g2 subunit are
associated with generalized epilepsies and febrile seizures. Here we describe a family that has generalized epilepsy
with febrile seizures plus (GEFS+), including an individual with severe myoclonic epilepsy of infancy, in whom a
third GABAA-receptor g2-subunit mutation was found. This mutation lies in the intracellular loop between the
third and fourth transmembrane domains of the GABAA-receptor g2 subunit and introduces a premature stop
codon at Q351 in the mature protein. GABA sensitivity in Xenopus laevis oocytes expressing the mutant g2Q351X
subunit is completely abolished, and fluorescent-microscopy studies have shown that receptors containing GFP-
labeled g2Q351X protein are retained in the lumen of the endoplasmic reticulum. This finding reinforces the involve-
ment of GABAA receptors in epilepsy.
Generalized epilepsy with febrile seizures plus (GEFS
[MIM 604233]) is now a well-recognized syndrome
(Scheffer and Berkovic 1997; Moulard et al. 1999; Singh
et al. 1999; Alekov et al. 2001; Baulac et al. 2001; Es-
cayg et al. 2001; Wallace et al. 2001b). The phenotypes
in families with GEFS include typical febrile seizures
(FS) seen in early childhood, as well as febrile seizures
plus (FS) in which either attacks with fever extend be-
yond age 6 years or afebrile generalized tonic-clonic sei-
zures (GTCS) occur. Less common phenotypes include
FS/FS associated with absence, myoclonic, atonic, or
partial seizures, and even refractory syndromes with de-
velopmental delay, such as myoclonic-astatic epilepsy
(MAE) and severe myoclonic epilepsy of infancy (SMEI)
(Singh et al. 2001).
Mutations in three voltage-gated Na-channel genes
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have been associated with GEFS. We first described a
mutation in the Na channel b1-subunit gene (SCN1B)
on chromosome 19q in a large family with GEFS and
showed that such phenotypic heterogeneity could be as-
sociated with the segregation of a single mutation (Wal-
lace et al. 1998). Subsequently, mutations were described
in the a1-subunit gene (SCN1A) on chromosome 2q in
other families with GEFS (Escayg et al. 2000, 2001;
Wallace et al. 2001b), as were more-severe de novo trun-
cation mutations in patients with SMEI (Claes et al.
2001). Sugawara et al. (2001) also recently implicated
the Na channel a2-subunit gene (SCN2A) in GEFS.
The spectrum of mutations that so far have been found
in these three Na-channel genes clearly demonstrates
Na-channel dysfunction in GEFS in ∼10%–20% of
probands (Sugawara et al. 2001; Wallace et al. 2001b).
Although sporadic examples of severe phenotypes such
as SMEI may be due to de novo truncation mutations
(Claes et al. 2001), such syndromes within families are
probably due to interaction between mutations at two
or more loci.
Recently, it has been shown that mutations in GABAA-
receptor subunits also play a significant role in contrib-
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Table 1






1 GCATGAGTATACACGAGTGTGC GCCTCTTGGTTGCAGAAGAATC 314
1 CAGTGAAGGACCTACTAGAGG GTAAAGCCGCACATCCTAGGAG 354
2 CAGTTAGTCTCCATCTATGCAG CCTTGCTCTTGAACTACACTG 414
3 TATGCGTGCTTGGTGCATGTGC GGATCTGGAAGACTATCTTTCAC 420
4 GTGAGACAGTAACCTCCTCAGC GATAGCATGCCAACCCTGATGC 520
5 CCTGGACTTGGTGGATTTCTTC TCACCCTAATCGGAGCAAGCTG 413
6 TGCCCTTTGGTCCAAGATCCTC TCAACTCTGGAAGGGTCACTTG 323
7 GGGATTCAGTTCAGGTTGTG GGGTTGGTTCCAAGTCTTTGC 524
8 CCACTTATACCTCCTTTCCC CGTTATGGCCTGGCTAAACTC 480
9 CATCACATTGGTGACATTGTGG ACATCTCTCCATGAGACTCAGT 419
9 TATTGGGTCTCCTACCTCTACC CCACTACTGTAAATAGTCAGGGC 345
a More than one PCR was required to amplify exons 1 and 9.
uting to the GEFS phenotype (Baulac et al. 2001; Wal-
lace et al. 2001a). GABAA receptors are pentameric
ligand-gated Cl channels primarily responsible for me-
diating fast inhibitory neurotransmission in the mam-
malian central nervous system (Barnard et al. 1998;
Schwartzkroin 1998). It has been known for some time
that disruption of GABA-mediated pathways is associ-
ated with epilepsy (Olsen et al. 1999), but specific mu-
tations contributing to this have only recently been iden-
tified. Baulac et al. (2001) described a mutation, in the
GABAA-receptor g2 subunit, that segregates in a French
family with GEFS. This mutation, K289M, changes a
highly conserved amino acid in the extracellular loop
between the second and third transmembrane domains,
and expression of this mutation in Xenopus laevis oo-
cytes resulted in a decrease in the amplitude of GABA-
activated currents. This discovery was the first genetic
evidence that GABAA-receptor dysfunction is associated
with GEFS.
Simultaneously, we described a missense mutation in
the GABAA-receptor g2-subunit gene in a large Austra-
lian family with epilepsy, in which the two main phe-
notypes were childhood absence epilepsy (CAE) and FS
(Wallace et al. 2001a). This mutation, R43Q, changes
a highly conserved amino acid residue in the first of two
extracellular high-affinity benzodiazepine-binding do-
mains. Although X. laevis oocytes expressing this altered
protein were still responsive to GABA, the mutation
abolished in vitro sensitivity to diazepam. Because of the
complex inheritance of CAE, we hypothesized that this
mutation may be primarily responsible for the expres-
sion of FS but that a second gene or genes are required
for the CAE phenotype (authors’ unpublished data). In
this pedigree there were three individuals with FS and
two with MAE, confirming that the R43Q mutation in
GABRG2 also contributes to the GEFS syndrome.
In a screen of 1200 unrelated patients with various
epilepsy phenotypes (GEFS, FS, and IGE) by single-
strand conformation polymorphism (SSCP) analysis, we
found another family with a novel GABRG2 mutation.
Hex-labeled primers were designed to amplify all nine
exons of the g2-subunit gene GABRG2 on chromosome
5q (table 1). SSCP and sequencing was performed as
described elsewhere (Wallace et al. 2001b). An SSCP
variant that was not detected in 96 unaffected control
samples was found in exon 9 of GABRG2 in several
individuals of a family with GEFS (fig. 1). This family
was initially described as “family G” by Singh et al.
(1999) and has been extended in the present study. The
proband (V-21) had a bilineal family history of seizures.
Information was obtained on 156 family members. On
the paternal side, there were seven individuals with sei-
zures: five with FS, one with FS, and one with FS and
absence seizures. The proband’s mother (IV-13) had
multiple FS, and her brother (IV-11) and his daughter
(V-17) also had FS.
The proband (V-21) had a severe phenotype of GEFS,
which was initially regarded as MAE, but further history
showed that she had SMEI. She had multiple clonic sei-
zures affecting the right upper limb, associated with fever
at age 3 mo. She had many such focal febrile seizures,
as well as afebrile GTCS, but she did not have convulsive
status epilepticus. Absence, myoclonic, and atonic sei-
zures began at age 3–4 years. Myoclonus involving both
upper limbs (right more than left) was prominent on
examination and was exacerbated with lamotrigine. The
proband had clinical photic sensitivity. From age 17
years, she had continuous irregular myoclonus of her
right upper limb; by age 22 years, she had 1–2 GTCS/
year and 1–2 absence seizures/d. Electroencephalogram
(EEG) readings became more active over time and
showed frequent paroxysms of irregular generalized
polyspike-wave activity brought out by photic stimu-
lation. Results of a magnetic-resonance imaging brain
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Figure 1 Pedigree of an Australian family with GEFS. An asterisk (*) indicates members carrying the Q351X mutation in GABRG2,
and a minus sign () indicates members who were tested and are negative for the Q351X mutation.
Figure 2 Sequencing trace of a portion of exon 9 GABRG2,
showing the c.1168CrT transition (arrow). The upper chromatogram
shows the mutation, and the lower chromatogram shows the control
sequence.
scan were normal. Early motor developmental mile-
stones were normal, but speech was delayed. Neuropsy-
chological assessment at age 14 years placed her in the
moderately intellectually disabled range, without later-
alizing features.
The proband had three brothers, two of whom had
a history of seizures. The youngest brother (V-20) had
six FS at age 2–3 years. The middle brother (V-19) had
MAE, with onset of absence and myoclonic seizures at
age 2 years. At age 4 years, GTCS developed. Treatment
was changed from phenytoin to valproate, at age 4 years
9 mo, and he became seizure free; valproate was ceased
at age 8 years. Recurrence of GTCS occurred at age 15
years, and valproate was recommenced. EEG studies at
age 4 years showed frequent paroxysms of generalized
polyspike-wave activity, and by age 8 years, photic sen-
sitivity was evident. Motor milestones were normal but
speech was delayed. He left school after his 10th year
there and has subsequently performed factory work.
DNA sequencing of the SSCP variant revealed a
CrT transition at nucleotide position 1168 of the
GABRG2 cDNA sequence (GenBank accession num-
ber nm_000816; fig. 2). This single-base substitution
introduces a premature stop codon at Q351 in the
mature GABRG2 protein in the large cytoplasmic loop
between the third and fourth transmembrane domains
(fig. 3), resulting in a truncated GABRG2 protein with
complete loss of the fourth transmembrane domain.
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Figure 3 Schematic representation of the GABRG2 protein, with
arrows indicating the positions of mutations associated with epilepsy.
Figure 4 Two-electrode voltage-clamp recordings in oocytes,
demonstrating that coexpression of the GABRG2Q351X abolishes the
response to GABA. For all recordings, . The current and timenp 6
scale bars apply to all traces. Holding potential was 80 mV. A,
Injection of oocytes with wild-type GABRA1:GABRB2:GABRG2
cRNAs (1:1:10 ratio, to favor assembly of g subunit–containing com-
plexes), resulting in both a robust inward current response to GABA
and a low sensitivity to Zn2 blockade, characteristic of GABRG2
coexpression. B, Expression of GABRA1:GABRB2 only (1:1 ratio).
This also produced robust responses to GABA, but with high sensitivity
to blockade by Zn2. C, Expression of GABRA1:GABRB2:
GABRG2Q351X subunits (1:1:10 ratio), abolishing GABA-induced
currents.
Individual IV-13, who has FS, and her two children,
V-20 and V-21, who have FS and SMEI, respectively,
all had the Q351X mutation. However, her son (V-
19) with MAE and her brother (IV-11) with FS both
tested negative for the truncation mutation. This fam-
ily has bilineal inheritance of seizure disorders, and
we speculate that the MAE in individual V-19 is due
to inheritance, from his father (IV-14), of a different
mutation, which is associated with GEFS phenotypes
in his extended family. This second mutation may also
contribute to the more severe phenotype observed in
V-21. The gene or genes responsible for the febrile
seizures in IV-11 and V-17 are unknown and could
also be contributing to the more severe phenotypes in
the proband and in her brother with MAE, where it
is likely that a number of genes are involved. Indi-
viduals III-8, III-9, IV-12, V-17, and V-18 were not
tested, since blood was not available. The generalized
epilepsies typically follow a complex inheritance pat-
tern. It is possible that complex inheritance occurs in
this multiplex family, since (a) at least three genes are
implicated, (b) bilineal inheritance occurs in the pro-
band’s nuclear family, and (c) phenotypic heteroge-
neity is prominent. However, we also acknowledge
that it is possible that three separate genes are re-
sponsible for the epilepsy seen in this family. Thus,
the finding of the Q351X GABRG2 mutation in only
three family members forms only one part of the in-
heritance pattern in this family.
To determine the functional consequences of the
Q351X mutation, GABA-mediated currents in X. laevis
ooctyes were measured in oocytes expressing the mutant
g2 subunit. A stop codon was introduced at amino acid
position 351 in the mature human GABRG2 protein, by
PCR-based mutagenesis using the primer pair 5′-GTGA-
AGACAACTTCCGGAGATTATGTGG-3′ and 5′-GC-
GAATTCATTAAATGGTTGCTGATCTTGGGCG-3′.
Female X. laevis oocytes were co-injected with the c-
RNAs encoding the a1 (GABRA1) and b2 (GABRB2)
subunits of the GABAA receptor, with either the wild-
type g2-subunit cRNA or the mutant truncated g2Q351X-
subunit cRNA, through use of standard procedures (Stu-
hmer 1998). GABAA receptors occur naturally in a
pentameric complex and are thought to consist of two
a subunits, two b subunits, and one g subunit (Klaus-
534 Am. J. Hum. Genet. 70:530–536, 2002
Figure 5 Imaging of GFP-tagged GABRG2 expressed with GABRA1 and GABRB2 subunits, revealing the fate of GABRG2Q351X-containing
receptors in HEK293 cells. Images were obtained by confocal fluorescence microscopy (excitation, 488 nm; emission, 1515 nm). The scale bar
in panel C corresponds to 5 microns and applies to all three panels. A, EGFP-tagged wild-type GABRG2 subunit, found in both the membrane
and the intracellular compartment ( individual cells analyzed). B, EGFP-tagged GABRG2Q351X, found only in the intracellular compartmentnp 20
( individual cells analyzed). C, ER-targeted EYFP expression, demonstrating subcellular distribution of ER that is remarkably similar tonp 20
that seen in B.
berger et al. 2000). Oocytes simultaneously expressing
all three wild-type subunits produced robust responses
to GABA (fig. 4A). In vitro studies have also shown that,
in the absence of GABRG2, complexes composed of a
and b subunits are functional but have altered phar-
macology (Draguhn et al. 1990; Connolly et al. 1996).
Coexpression of GABRA1 and GABRB2 results in
GABA-activated currents that are extremely sensitive to
blockade by Zn2 (fig. 4B), unlike currents from com-
plexes formed with GABRG2 (fig. 4A). The functional
consequences of the Q351X mutation of the GABRG2
subunit was assessed by expression of this mutant with
wild-type a and b subunits. In this case, application of
GABA failed to activate current responses (fig. 4C), sug-
gesting that the mutant not only fails to assemble cor-
rectly with a and b subunits (compare to fig. 4A) but
also interferes with the ability of the a and b subunits
themselves to assemble into functional complexes (com-
pare to fig. 4B).
To assess the cellular fate of receptor complexes har-
boring the GABRG2Q351X mutant subunit, GFP-tagged
wild-type and mutant GABRG2 subunits were engineered
and then transfected into HEK293 cells, for analysis of
spatial distribution with confocal fluorescence micros-
copy. Previous work has shown that fusion of GFP to the
N-terminus of GABRG2 is functionally silent (Kittler et
al. 2000). The N-termini of wild-type and mutated
GABRG2 were tagged with enhanced green-fluorescent
protein (EGFP), by use of Clontech’s pEGFP-C1 vector,
to create GFP-GABRG2 and GFP-GABRG2Q351X. Recep-
tor complexes composed of GABRA1:GABRB2:GFP-
GABRG2 were found to localize to the cell membrane
(fig. 5A) and intracellular compartment. When the wild-
type GFP-GABRG2 was replaced by GFP-GABRG2Q351X,
plasma-membrane–specific fluorescence was absent (fig.
5B). Instead, a reticular fluorescent pattern was observed,
similar to that seen in the intracellular compartment of
cells transfected with the wild-type GFP-GABRG2. In
no case did we observe membrane localization of the
GFP-GABRG2Q351X ( cover slips with 1400 cellsnp 6
screened). This fluorescent pattern was also similar to
that observed by transfection of HEK-293 cells with
either Clontech’s endoplasmic reticulum (ER)–targeted
pEYFP-ER vector (fig. 5C; BD Biosciences Clontech) or
the fluorescent dye, DiOC6. Both markers reveal the lo-
calization of ER, suggesting that the GFP-GABRG2 Q351X
is retained in the ER. Earlier work on the assembly of
truncated nicotinic acetylcholine–receptor subunits that
lack transmembrane domains (Verrall and Hall 1992) ad-
vanced the idea that, although truncated subunits assem-
ble successfully with full-length subunits, the lack of a
transmembrane anchor traps the assembled complex in
the lumen of the ER. This proposed mechanism may pro-
vide an explanation for the truncated GABRG2 protein’s
lack of cell-surface expression in the present study. The
implication for individuals heterozygous for the Q351X
mutation would be that the truncated receptor subunit
reduces the density of functional GABAA receptor com-
plexes on the cell surface, leading to a decreased inhibitory
response to GABA and, consequently, to increased neu-
ronal excitability and seizures. Therefore, truncation of
the GABAA-receptor g2 subunit most likely contributes
to the seizures seen in three affected members of this fam-
ily (individuals IV-13, V-20, and V-21; fig. 1).
The Q351X mutation described in the present article
appears to cause dysfunction similar to that created by
the K289M mutation described by Baulac et al. (2001),
in that they both cause complete or partial loss, respec-
tively, of GABA sensitivity and are both associated with
families that have GEFS. In contrast, the R43Q mu-
tation that we previously had described in a family with
CAE and FS had no effect on GABA-mediated currents
but completely abolished sensitivity to benzodiazepines.
It is possible that complete or partial loss of GABA sen-
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sitivity is associated with the typical GEFS phenotype,
whereas disruption of the benzodiazepine receptor, leav-
ing GABA sensitivity intact, results in the CAE/FS phe-
notype. We hypothesize that the position and/or severity
of the mutation in the GABAA-receptor subunit may de-
termine the spectrum of overlapping phenotypes. This
has been shown in the Na-channel–subunit SCN1A
gene, where different mutations result in different phe-
notypes. A number of families with single amino acid
substitutions that are associated predominantly with
mild GEFS phenotypes have been described, whereas
severe mutations occur in sporadic SMEI (Escayg et al.
2000, 2001; Claes et al. 2001; Wallace et al. 2001b).
The identification of different GABRG2 mutations in
different families reinforces the importance of this sub-
unit in human epilepsies. Like the Na channelopathies,
where GEFS-associated mutations have now been iden-
tified in a number of different Na-channel subunits, it
is likely that other GABAA-receptor subunits contribute
to GEFS phenotypes.
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